The merger of 2 leading providers of hearing implants could lead to higher prices for the NHS, and reduced quality and slower innovation for UK patients who rely on these life-changing devices.
The Competition and Markets Authority (CMA) is concerned that Cochlear’s proposed purchase of Oticon Medical – the hearing implant division of Demant –would have a negative impact on patients who need hearing implants, the majority of whom access these through the NHS.
Related: UK Watchdog Says Streaming Music Is Fair To Both Consumers & Artists
Cochlear and Demant are both global suppliers of cochlear implants and bone conduction solutions, which are types of hearing devices that are surgically implanted. These devices help improve hearing for people with mild to severe or total hearing loss but serve different patient needs depending on the cause of each individual’s hearing loss.
Following its Phase 1 investigation, the CMA found that the proposed deal would result in the merged businesses having a 90-100% share of the bone conduction solutions market in the UK. Should the deal go ahead as planned, the CMA is concerned that this would result in the elimination of the strongest competitor in this segment (Oticon Medical), which could lead to reduced innovation, higher prices or less choice for hospitals and their patients.
The CMA also investigated the impact of the merger on the supply of cochlear implants, where Cochlear has a very strong position. It found that, in the UK, Oticon Medical has only had a very small position in this segment, is not a significant rival of Cochlear and was unlikely to become a significant rival in the future. The CMA also found that the merged businesses would still face competition from 2 other providers in the UK, both of whom offer a stronger constraint on Cochlear than Oticon Medical. As such, the CMA’s competition concerns only relate to bone conduction solutions.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI